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To investigate the awareness of diabetic retinopathy (DR) among diabetics in the Cape Town 
Metropole by assessing: 
• Whether diabetics know that diabetes can affect their eyes.
• Whether the awareness of DR differs according to subtype of diabetes, place of treatment
(private versus public sector), level of education and socio-economic status.
• Knowledge of systemic risk factors for developing DR.
• Knowledge of treatment of DR.
Methods 
A population-based cross-sectional study was conducted as part of the Rapid Assessment of 
Avoidable Blindness (RAAB) survey undertaken in 2010. For the RAAB survey, a sample size 
of 3077 was chosen based on 3% prevalence of blindness amongst people 50 years and over, 
25% precision rate, design effect of 1.4, 95% confidence level and a 10% non-response rate. In 
total, 77 clusters of 40 people were required. For logistical reasons, 82 clusters were included in 
the survey. 
For the DR component, a sample size of 2061 participants was required based on an expected 
DR prevalence of 4.5% and the parameters mentioned above. The 2001 census data, updated 
using expected population growth, was used as the sampling frame. Clusters (‘small areas’) were 
selected by probability proportionate to size. Two-thirds of the clusters were randomly allocated 
to the RAAB and Diabetic Retinopathy (RAAB+DR) survey, while the remaining clusters were 
only allocated to the RAAB survey. 
Results 
Of the 1784 eligible survey participants, 305 were known to be diabetic, and 226 (80%) of those 
were aware of DR.  Diabetics’ understanding of preventive measures was as follows: following a 
diabetic diet 43 (46%), using diabetic medication 126 (40%), maintaining good glycaemic 
control 54 (17%) and maintaining good blood pressure control 6 (2%).  Ninety diabetics (29%) 
did not know of any risk factors. Type 1 (insulin dependent) diabetics were significantly more 
aware of DR than type 2 (non-insulin dependent) diabetics (97% versus 75% respectively: p=< 
0.0001). There was no significant difference in awareness between diabetics receiving treatment 
in the private sector versus those receiving treatment in the public sector. Of the known diabetics, 
136 (48%) were aware that annual retinal examinations are required and 198 (70%) were not 
aware what the treatment for DR is. 
Conclusion 
Although a large proportion of diabetics in the Cape Metropole are aware that diabetes can affect 
their eyes, they have a poor understanding of prevention of DR through control of the systemic 
risk factors, of the importance of annual retinal examinations and of the treatment of DR. 
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Diabetics’ understanding of the risk factors for developing DR, the need for retinal examinations 
and the treatment of DR, need to be greatly improved in order to decrease the number of cases of 
blindness resulting from DR in Cape Town. 
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Diabetes mellitus (DM), particularly type 2 diabetes, is a major public health concern worldwide. 
According to the World Health Organization (WHO), over the next two decades there will be a 
significant increase in the number of people with type 2 diabetes mellitus, both in developed and 
developing countries. In the developed world, the estimated increase is approximately 46%, from 
55 million in 2000 to 83 million in 2030. In developing nations, such as South Africa, the 
estimated increase is approximately 150%, from 30 million in 2000 to 80 million in 2030.(1) 
Diabetic retinopathy (DR) is a potentially blinding complication of diabetes and is the leading 
cause of blindness in working-age populations in high-income settings.(2) DR is expected to 
become an increasingly dominant cause of vision loss in low- and middle-income countries 
(LMICs) as the diabetes epidemic unfolds and other blinding conditions such as cataracts are 
better controlled. With the growing burden of diabetes in LMICs, reliable up-to-date estimates of 
DR prevalence are urgently required to plan appropriate DR services. However, few population-
based DR surveys have been undertaken in low- and middle-income settings.(3) Previous South 
African DR prevalence estimates are based on figures from health facilities that may not be 
generalizable.(4) 
The subjective experience of doctors working at Groote Schuur Hospital is that the majority of 
diabetics who present to the ophthalmology department are not aware that diabetes can affect 
their eyes, nor that they should have annual retinal examinations to detect diabetic retinopathy. 
This may be one of the reasons why a large number of diabetics present with advanced diabetic 
retinopathy. Also, many diabetics are not aware that there is treatment available once they have 
developed sight-threatening diabetic retinopathy (STDR). 
When advanced diabetic ophthalmic complications are presented to ophthalmologists, there is 
often a delay in referral. Poor awareness of the importance of regular eye examinations and the 
benefits of treatment among both primary care physicians and their patients may contribute to 
this delay.(5) One study revealed that people who were uninformed about diabetes care had a 
fourfold increased risk of major diabetes-related complications compared to those who were 
informed (5). 
The principal risk factors for the development and progression of DR are duration of diabetes, 
glycaemic control,(6) hypertension,(7) dyslipidaemia,(8) nephropathy,(9) and pregnancy(10). 
However, optimal metabolic and blood pressure control is not always achieved, and even among 
patients with good control of the systemic risk factors, DR may develop and progress. Therefore 
active screening is used in many countries to ensure that STDR can be recognised and treated by 
laser photocoagulation before it causes visual impairment. In the 1980s, the Early Treatment 
Diabetic Retinopathy Study (ETDRS) found that among patients with clinical significant 
macular edema, the risk of visual loss of those patients that received focal photocoagulation was 
halved.(11) The Diabetic Retinopathy Study (DRS) found that among patients with proliferative 
diabetic retinopathy, laser photocoagulation reduced the risk of severe visual loss from 16.3% to 
6.4% at two years.(12) 
It does not appear from the literature available that any population-based studies on the 
awareness of diabetic retinopathy among diabetics in Africa have been conducted. In this study, 
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a number of aspects were explored, such as diabetics’ lack of awareness of DR as a possible 
complication of diabetes, and issues such as adherence to DR screening guidelines. The ‘DR 
awareness’ study is part of a larger study: the Rapid Assessment of Avoidable Blindness and 
Diabetic Retinopathy (RAAB+DR) survey. 
The following data will be collected from previously diagnosed diabetics: 
• Subtype of diabetes (based on medication used, such as oral agents and/or insulin)
• Awareness of:
o DR as a possible complication of diabetes
o The systemic risk factors for developing STDR
o The availability and type of treatment for STDR.
• Prior retinal screening examinations
• Whether a retinal examination has been performed in the preceding year
• Socio-economic status
• Highest education level achieved.
The RAAB is a relatively simple, affordable population-based survey methodology that provides 
district-level data on the prevalence and causes of blindness among people aged 50 years and 
over.(13) An additional component to RAAB was recently developed to estimate the prevalence 
of diabetes and DR (RAAB+DR). The aim was to generate relatively low-cost data for the 
planning of DR services. This method has been piloted in Mexico(14), but it still needs to be 
tested in different settings to assess its reliability and resource requirements. 
The prevalence of diabetes in South Africa is significant and increasing. The prevalence of 
diabetes in Cape Town in people over 30 years of age is 8%, with 260 000 diabetics being cared 
for at a primary level.(15) Approximately 11% of these diabetics have regular eye 
examinations.(16) Glycaemic control is suboptimal, with 49.4% (95% CI 45–53%) of public 
sector patients having a HBA1C (glycated haemoglobin count) of less than 7%.  Poor glycaemic 
control has been shown to be associated with the increased incidence and progression of DR(17) 
in both type 1 and type 2 diabetes.(18) 
In this context, it is imperative to investigate and improve diabetics’ understanding of the various 
aspects of diabetic eye disease. 
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Aim 
To assess the awareness of diabetic retinopathy and other related factors among diabetics in the 
Cape Town Metropole. 
Specifically this study will investigate: 
1. Whether diabetics know that diabetes can affect their eyes.
2. Whether there are differences in awareness of DR between the different subtypes of diabetes.
3. Whether there is a correlation between:
a. Diabetics’ level of education and their awareness of DR.
b. Diabetics’ socio-economic strata and their awareness of DR.
4. Diabetics’ understanding of the risk factors that play a role in the development of DR.
5. Diabetics’ understanding of the need for screening examinations to detect DR and the
recommended frequency of those examinations.
6. Diabetics’ understanding of the treatment for STDR.
Materials and methods 
A RAAB survey will be undertaken in the Cape Town Metropole between September 2010 and 
November 2010. A DM and DR component will be included in selected clusters (RAAB+DR). 
Study sample 
For the RAAB survey, a sample size of 3077 will be selected based on a 3% prevalence of 
blindness amongst people aged 50 years and over, a 25% precision rate, a design effect of 1.4, a 
95% confidence rate and a 10% non-response rate. In total, 77 clusters of 40 people will be 
required. For logistical reasons, 82 clusters will be included in the survey. For the DR component, 
a sample of 2061 participants will be required (52 clusters of 40 people), based on an expected 
DR prevalence of 4.5%(14) and the parameters mentioned above. 
The 2001 census data will be used as the sampling frame and updated using expected population 
growth. Clusters (‘small areas’) will be selected by probability proportionate to size. Two-thirds 
of the clusters will be randomly allocated to the RAAB+DR survey, while the remaining clusters 
will only be allocated to the standard RAAB survey.  
Rapid assessment of avoidable blindness 
Detailed descriptions of RAAB methods are presented in other literature.(13) In summary, 
households within clusters will be selected using ‘compact segment sampling’, whereby one 
segment containing approximately 40 (or 35) people aged 50 years or over is randomly selected 
for each cluster.(19) The survey team will conduct door-to-door household visits in selected 
segments to identify eligible people until the target cluster size is reached.  Visual acuity (VA) 
will be measured using a tumbling ‘‘E’’ chart.  People whose eyes have a VA of less than 6/18 
will be examined by the ophthalmologist to assess the main cause of vision loss. 
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Diabetes mellitus and diabetic retinopathy component 
In the RAAB+DR clusters, all participants will be asked whether they have ever been diagnosed 
with diabetes by a health professional and whether they are taking diabetic medication. Random 
blood glucose (RBG) will be tested in all participants using a digital glucometer. Participants 
will be classified as diabetic if they have had a previous diagnosis of diabetes, are receiving 
treatment for glucose control, or have a RBG ≥11.1 mmol/l.(20)  
Additional variables 
Data will be collected on age, gender, education, and asset ownership, from which a socio-
economic status (SES) index will be created using principal component analysis.(21) Previously 
diagnosed diabetics will be asked about their history of diabetes and eye examinations. 
Survey teams and training 
The questionnaire was compiled in English and Afrikaans. The two versions of the questionnaire 
will be piloted on two consecutive days to assess whether patients understand the questions and 
whether the answers can be matched to the options on the questionnaire. There will be five 
survey teams, each consisting of one ophthalmologist and two community-based eye workers. 
The survey teams will receive six days of training.    
Ethical considerations 
Informed written consent will be obtained from all participants. Ethical approval was granted by 
the University of Cape Town Health Sciences Human Ethics Committee and the London School 
of Hygiene & Tropical Medicine.  All participants with ophthalmic conditions that require 
treatment or further investigation will be referred accordingly. People with newly diagnosed or 
poorly controlled diabetes will be referred to the nearest health centre. 
The questionnaire 
A questionnaire will be completed by all known and newly diagnosed diabetics in the sample. 
Data analysis 
The same data will be entered into two databases by two different people. Inconsistencies in the 
data entered will be identified using Epi InfoTM (epidemiology statistical software), and 
corrections will be made by referring back to the original data capture sheets. The data will then 
be analysed using STATA 11 (data analysis and statistical software). 
Expected outputs 
The data from the proposed study could provide information on the awareness of diabetics in the 
Cape Town Metropole of the potential secondary ocular complications of diabetes. 
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The information could be used for DR awareness advocacy and to inform planning of eye care 
services in Cape Town. The findings of this study could well be generalizable to other urban 
populations in other Southern African countries with intermediate economies. 
References 
(1) Rani PK, Raman R, Subramani S, Perumal G, Kumaramanickavel G, Sharma T. Knowledge
of diabetes and diabetic retinopathy among rural populations in India, and the influence of
knowledge of diabetic retinopathy on attitude and practice. Rural Remote Health 2008 Jul-
Sep;8(3):838.
(2) Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in
England & Wales. BMC Public Health 2006 Mar 8;6:58.
(3) Raman R, Rani PK, Reddi Rachepalle S, Gnanamoorthy P, Uthra S, Kumaramanickavel G, et
al. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy
Epidemiology and Molecular Genetics Study report 2. Ophthalmology 2009 Feb;116(2):311-
318.
(4) Read O, Cook C. Retinopathy in diabetic patients evaluated at a primary care clinic in Cape
Town. S Afr Med J 2007 Oct;97(10):941-2, 944.
(5) Muecke JS, Newland HS, Ryan P, Ramsay E, Aung M, Myint S, et al. Awareness of diabetic
eye disease among general practitioners and diabetic patients in Yangon, Myanmar. Clin
Experiment Ophthalmol 2008 Apr;36(3):265-273.
(6) Progression of retinopathy with intensive versus conventional treatment in the Diabetes
Control and Complications Trial. Diabetes Control and Complications Trial Research Group.
Ophthalmology 1995 Apr;102(4):647-661.
(7) Tight blood pressure control and risk of macrovascular and microvascular complications in
type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 Sep
12;317(7160):703-713.
(8) van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood
pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 2002
Aug;25(8):1320-1325.
(9) Klein R, Moss SE, Klein BE. Is gross proteinuria a risk factor for the incidence of
proliferative diabetic retinopathy? Ophthalmology 1993 Aug;100(8):1140-1146.
(10) Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy.
Diabetes Care 1990 Jan;13(1):34-40.
PAGE 11 
(11) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study
report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol
1985 Dec;103(12):1796-1806.
(12) Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of
Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy
Study Research Group. Ophthalmology 1981 Jul;88(7):583-600.
(13) Kuper H, Polack S, Limburg H. Rapid assessment of avoidable blindness. Community Eye
Health 2006 Dec;19(60):68-69.
(14) Polack S, Yorston D, Lopez-Ramos A, Lepe-Orta S, Baia RM, Alves L, et al. Rapid
assessment of avoidable blindness and diabetic retinopathy in chiapas, Mexico. Ophthalmology
2012 May;119(5):1033-1040.
(15) Mash B, Powell D, du Plessis F, van Vuuren U, Michalowska M, Levitt N. Screening for
diabetic retinopathy in primary care with a mobile fundal camera--evaluation of a South African
pilot project. S Afr Med J 2007 Dec;97(12):1284-1288.
(16) Govender I, Ehrlich R, Van Vuuren U, De Vries E, Namane M, De Sa A, et al. Clinical
audit of diabetes management can improve the quality of care in a resource-limited primary care
setting. Int J Qual Health Care 2012 Dec;24(6):612-618.
(17) Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts
the incidence and progression of diabetic retinopathy. JAMA 1988 Nov 18;260(19):2864-2871.
(18) Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year
update of a randomized, controlled trial on the effect of improved metabolic control on
complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996 Jan 1;124(1 Pt
2):136-145.
(19) Turner AG, Magnani RJ, Shuaib M. A not quite as quick but much cleaner alternative to the
Expanded Programme on Immunization (EPI) Cluster Survey design. Int J Epidemiol 1996
Feb;25(1):198-203.
(20) Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser
1985;727:1-113.
(21) Filmer D, Pritchett LH. Estimating wealth effects without expenditure data--or tears: an
application to educational enrollments in states of India. Demography 2001 Feb;38(1):115-132.
PAGE 12 
B. Literature review
The number of people with diabetes in the world is increasing due to population growth, 
population ageing, urbanisation and the increasing prevalence of obesity and inactivity. In 2000, 
the number of cases of diabetes worldwide was estimated to be 171 million.(1) 
According to the World Health Organization (WHO), over the next two decades there will be a 
significant increase in the numbers of people with type 2 diabetes mellitus, both in developed 
and developing countries. In the developed world, the estimated increase is approximately 46%, 
from 55 million in 2000 to 83 million in 2030, whereas among developing nations, the estimated 
increase is approximately 150%, from 30 million in 2000 to 80 million in 2030.(2) Population-
based surveys performed in urban Sub-Saharan Africa have estimated the prevalence of diabetes 
to be between 1.5% among people aged 24–74 years old in Cameroon, and 8.2% among people 
aged 25 years and older in South Africa. The estimated prevalence in urban South Africa is 
between 4.4% among people aged 15 years and older, and 8.2% among people aged 25 years and 
older.(3) 
Current estimates of the prevalence of DR among people with diabetes in developing regions 
range from 19% in Bangladesh, 17–22% in India, 30.3% in Cambodia, 37% in Iran, 43.1% in 
rural China and 63% in South Africa. Many of these studies have demonstrated comparable rates 
to those observed in developed nations such as Australia, UK and the USA, which have a 29.3%, 
39% and 50.3% prevalence of DR among diabetics respectively.  
The principal risk factors for the development and progression of diabetic retinopathy are 
duration of disease, poor control of diabetes,(4) hypertension,(5) pregnancy,(6) dyslipidaemia(7)  
and nephropathy.(8)  The implications of untreated DR are significant, not only in terms of loss 
of quality of life, but also financially.(9) Blindness caused by diabetes is estimated to cost the 
USA $500 million dollars annually.(9) 
In the 1980s, the Early Treatment Diabetic Retinopathy Study (ETDRS) found that among 
patients with clinically significant macular edema, the risk of visual loss of those patients that 
received focal retinal photocoagulation was halved.(10) The Diabetic Retinopathy Study (DRS) 
found that among patients with proliferative diabetic retinopathy, laser photocoagulation reduced 
the risk of severe visual loss from 6.4% to 16.3% at two years.(11) Recent studies indicate that a 
large proportion (37–79%) of the diabetic population is not following recommended guidelines 
to prevent visual impairment and blindness. The American Academy of Ophthalmology and the 
American Diabetes Association have published guidelines regarding the timing and frequency of 
dilated retinal examinations in diabetics, the aim being to detect retinopathy in its most treatable 
stages. Type 1 diabetics should have annual examinations beginning five years after diagnosis, 
and type 2 diabetics should have an examination at the time of diagnosis of diabetes and at least 
annually thereafter.(12,13)   Despite comprehensive reporting of the DRS and ETDRS findings 
over a decade ago, and the development of DR screening guidelines, the translation and adoption 
of these guidelines into clinical practice has been lagging, raising increasing concern among 
vision care professionals.(9) 
PAGE 13 
Objectives 
The objectives of the literature review were to investigate: 
1. Diabetics’ awareness of DR elsewhere in the world.
2. Diabetics’ understanding of the risk factors that play a role in the development of DR.
3. Diabetics’ awareness of the need for annual retinal screening examinations to detect STDR.
4. Diabetics’ understanding of the treatment for DR.
5. Whether there is a difference in awareness between diabetics receiving treatment in the
private sector versus those receiving treatment in the public sector.
6. Whether there is a correlation between a person’s awareness of DR and their level of
education.
7. Whether there is a correlation between a person’s awareness of DR and their socio-economic
status.
8. Whether there is a difference in awareness of DR between type 1 and type 2 diabetics.
Literature search strategy 
The PubMed library was searched using the following keywords: 




Summary and interpretation of the literature 
The literature review revealed 13 journal articles on the awareness of diabetic retinopathy 
amongst diabetics.  
 
Table 1: Studies on the awareness of diabetic retinopathy 























204 2004 52.9% 
Israel(17) Hospital-based cross-
sectional survey 
165 2000 35% 
Italy(18) Institution-based cross-
sectional survey 
70 2002 84% 
Japan(19) Cohort Study 1333 2003 98% 
Maryland, USA(20) Population-based cross-
sectional survey 
204 2008 52% 
Myanmar(1) Institution-based cross-
sectional survey 
200 2008 86% 
Nepal(21) Hospital-based cross-
sectional survey 
210 2012 63% 
Singapore(22) Population-based cross-
sectional survey 
227 2013 15.3% 
Turkey(23) Hospital-based cross-
sectional survey 
181 2013 88.1% 
Wales(18) Institution-based cross-
sectional survey 
128 2002 65% 
 
1. Level of awareness of DR amongst diabetics 
It appears from the literature that diabetics’ level of awareness of DR as a possible complication 
of diabetes varies widely, being very high in Italy(24), Japan(25), Myanmar(1) and Turkey(23) 
and poor in Israel, India,(2,14,15,26) Maryland(20) and Singapore(22). One would expect clinic- 
or hospital-based studies to show higher levels of awareness, as attendance at clinics and 
hospitals implies contact with health professionals and therefore possibly more exposure to 
information and counselling. 
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1.1 Awareness of DR between diabetics receiving care in the private sector versus diabetics 
receiving care in the public sector 
The literature on the awareness of DR did not include studies on whether there is any difference 
in awareness between patients in the private and the public sectors. It could be reasonable to 
assume that diabetics’ awareness in the public sector would be less than in the private sector, 
because public sector medical personnel have less time to spend with patients than private sector 
medical personnel. This study examines this possible relationship. 
 
1.2 Awareness of DR between type 1 and type 2 diabetics 
It could be assumed that type 1 diabetics have had diabetes for longer than type 2 diabetics and 
would therefore have spent more time in the health care system. The type 1 diabetics could 
therefore have had more exposure to health care providers and education about the complications 
of diabetes. The study done in Nepal(21) found no difference between awareness of DR in type 1 
versus type 2 diabetics.  
 
1.3 Awareness of DR and level of education 
Studies conducted in India (Hyderabad and Tamil Nadu),(2,14) Maryland,(20) Nepal,(21) 
Singapore(22) and Turkey(23), which examined the level of awareness of DR and people’s level 
of education, found that the higher the level of education, the higher the level of awareness of 
DR. It could be that diabetics who are better educated have a better understanding of the 
explanation given to them by medical personnel on diabetes, its complications, the importance of 
preventative strategies and the importance of regular eye examinations to detect STDR, which 
can be treated if diabetics present early.  
 
1.4 Awareness of DR and socio-economic status 
Three studies looked at the possible correlation between awareness of DR and socio-economic 
status. The studies done in India (Hyderabad, Tamil Nadu)(2,14) and Singapore(22) 
demonstrated that there was a lower awareness of DR amongst diabetics belonging to lower 
socio-economic strata. 
 
2. Awareness of the importance of an annual retinal examination 
 
2.1 The proportion of diabetics that was aware of the importance of a retinal examination 
The literature revealed five studies that reported on diabetics’ awareness of the importance of 
annual retinal examinations to detect STDR. Apart from a study done in Tamil Nadu, India, 
where it was found that 80% of diabetics were aware of the importance of retinal examinations, 
the studies showed that generally, diabetics had a poor awareness of the importance of having an 
annual retinal examination to detect STDR.(14,16,20,23) Almost all people with diabetes will 
experience some degree of diabetic retinopathy over time, with the prevalence increasing with 
the duration of the disease.(9) 
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2.2 Proportion of diabetics that have had a previous retinal examination 
Table 2 indicates that two-thirds of the diabetics in the studies in Japan and Turkey have had 
previous retinal screening examinations to detect DR.(23,25) The other studies showed that only 
half (or fewer) of the diabetics have had a previous examination.(15,16,25,27,28) An interesting 
finding in the studies conducted in India in Kanchipuram and Vellore(15) was that only half of 
the diabetics that were seen at a screening camp for diabetes mellitus attended the screening 
camp for diabetic retinopathy one week later. These studies suggest that a large proportion of 
diabetics have never had a retinal examination. 
 
Table 2: Awareness of the need for retinal examinations and the proportion that have had 
them 
 Awareness of the need 
to have annual retinal 
examinations 
Proportion that have 
had a previous exam 
Proportion that have 
had a retinal exam in 
the preceding 12 
months 




 50% of diabetics that 
had attended a 
diabetic screening 
camp attended a 
diabetic retinopathy 
screening camp a 
week later. 
55% of rural diabetics 
and 50% of urban 
diabetics with STDR. 
India 
(Hyderabad)(14) 
34.3%   
India 
(Tamil Nadu)(16) 
80% 56.5%  
Israel(17)  47% 35% 
Japan(19)  70%  
Myanmar(1) 23% 57%  
Maryland, USA(20) 48% 48% 30% 
Nepal(21)  50%  
New York, USA(30)  66%  
Turkey(23) 41.9% 77.3%  
 
 
2.3 Proportion of diabetics that have had a retinal examination in the preceding year 
Very little data have been published on the proportion of diabetics that go for annual screening 
retinal examinations. The literature review showed that those studies that dealt with this issue 
found that the majority of diabetics do not have annual retinal examinations as 
recommended.(15,20,28) The proportion of diabetics that have had a retinal examination in the 
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last 12 months ranged from 5.5% in Cape Town to 50% in Kanchipuram and Vellore in 
India.(15,27) 
 
These results imply that although the level of awareness of diabetics regarding diabetic 
retinopathy might be reasonable, a large proportion of diabetics have never had a screening 
retinal examination and/or do not have exams annually, as stipulated by diabetic retinopathy 
screening guidelines. The literature review identified several reasons why diabetics have a poor 
understanding of the importance of annual retinal screening examinations, why a large 
proportion of diabetics have not had a retinal examination, and why diabetics that have had eye 
examinations have not had  them annually, as recommended. 
 
2.4 Reasons identified by previous studies why a large proportion of diabetics do not go for 
screening retinal examinations 
One of the studies found that the reason why many people did not go for retinal screening 
examinations was that those people did not believe that they had retinopathy.(21)  Another 
reason was found to be poor awareness among patients and health care providers of retinopathy 
as a complication of diabetes. In some cases people knew that DM could affect their eyes, but 
were unaware that it could lead to blindness and that severe nonproliferative diabetic retinopathy 
(NPDR) can be asymptomatic.(15,21,31) These factors led to poor motivation among diabetics 
to go for eye examinations.(15) A study conducted in Myanmar revealed that only 49% of 
general practitioners (GPs) examined their diabetic patients’ eyes. Possible reasons for this were 
postulated to be a lack of ophthalmoscopy equipment, a lack of familiarity with ophthalmoscopic 
fundal examination techniques, a lack of familiarity with the ophthalmic signs of diabetes and 
the time constraints of a busy urban practice.(1) The study in Myanmar found that 34% of 
patients only decided to go for an exam once they had developed problems with their 
eyesight.(1,22) Cultural beliefs also played a role,(22) as did poor physician-patient 
communication(22) and poor literacy.(22) Other reasons included the belief that laser treatment 
was uncomfortable.(31) Overall, a general lack of awareness was the main barrier to people 
having eye examinations.(31) 
 
The patients themselves identified fear and guilt as key barriers that prevented them from 
attending clinics for retinal examination.(32) Although good control of blood sugar and blood 
pressure reduces the risk of ophthalmic complications, it does not eradicate the risk entirely.(31) 
Educators and physicians should avoid implying that retinopathy is due to patients’ carelessness 
and poor diabetic control, as this causes fear and guilt, which further prevents patients from 
attending clinics for retinal examinations.(31) 
 
Other factors identified by patients for nonattendance for retinal screening included clinic 
waiting times, social and employment concerns, such as the loss of income on the day of 
treatment.(32) Patients often end up spending the better part of a day at hospitals and clinics 
while having eye drops administered to dilate their eyes and waiting to be attended to. After 
being seen, some patients require laser treatment.(31) If patients need to come for regular follow 
up visits, some fear losing their jobs due to the frequent absenteeism.(31) Logistical concerns 
(distance of the hospital from where patients live and transport difficulties) are other cited 
barriers to retinal screening.(15) 
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3. Diabetics’ understanding of the risk factors that play a role in the development of DR and the 
treatment of STDR 
Only four studies were identified that reported on diabetics’ understanding of the risk factors that 
play a role in the development of DR. In a study conducted in Tamil Nadu, India, it was found 
that only 46.1% of patients were aware of the risk factors for the development of DR, and more 
alarmingly, only 44.9% of paramedical personnel were aware of the risk factors for the 
development of DR.(16) A study conducted in Italy found that 61% of diabetics were aware of 
the risk factors; a study in Maryland, USA, found that 34% of diabetics knew of the risk factors; 
and a study done in Wales found that 53% of diabetics were aware of the risk factors.(20,24) 
Although a limited number of studies examined this issue, it appears that a large proportion of 
diabetics have a poor understanding of the risk factors that play a role in the development of DR. 
 
Awareness of the treatments available for STDR may motivate diabetics to attend retinal 
screenings. Only two studies were identified that commented on diabetics’ understanding of the 
treatment available for treating STDR, both of which were conducted in India. In Hyderabad, it 
was found that 68.2% of diabetics were aware what treatment was available. In Tamil Nadu, 
29% of the community and only 24% of paramedics(14,16) were aware what treatment was 
available for DR. The paucity of published data shows that very little is known about patients’ 
awareness of the treatment of diabetic retinopathy. Both studies demonstrated that a large 
proportion of diabetics do not know that there is treatment available for STDR. 
 
3.1 Suggested methods to improve the awareness of DR amongst diabetics 
Methods to increase diabetics’ awareness of DR, the risk factors that play a role in the 
development of DR and the importance of annual eye examinations to detect STDR are 
postulated in the literature.   
 
There is a need for awareness campaigns about diabetic eye disease that involve social workers, 
voluntary organisations and local community leaders.(15) Screening examination reminders 
could be communicated to patients by telephone, sms, post, e-mail and visits by social 
workers.(15,31)  Educational programmes, such as group teaching sessions, leaflets, brochures, 
and greater publicity in the media are also recommended.(15,24)  Information should not only be 
provided about the ocular complications of diabetes, but also about the risk factors for 
developing DR, the importance of control of systemic risk factors,  what treatment is available 
for DR, and what that treatment entails. Screening retinal examinations of hospitalised diabetic 
patients were also found to be effective in creating a greater awareness of DR.(28) 
 
In terms of concerns about employment, the early involvement of social workers could mitigate 
against the fear of job loss due to absenteeism.(31)  Making screening available at a primary care 
level increases attendance, in part due to the fact that it is more convenient for patients.(31) 
Improving physician-patient communication is important, and any such engagements should be 
tailored according to patients’ levels of education.(22) 
 
4. Conclusion 
Diabetics have a poor understanding of the risk factors that play a role in the development of DR. 
Diabetics also have poor awareness of the need for annual retinal examinations and poor 
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awareness that treatment is available for the disease in the early stages. There are no published 
data dealing with awareness among diabetics receiving treatment in the public sector compared 
to those receiving treatment in the private sector. A correlation was found between the level of 
awareness of DR and the level of education, as well as between the level of awareness of DR and 
socio-economic status. Only two studies investigated whether there is a difference in awareness 
between the different subtypes of diabetes. There are numerous suggestions in the literature of 
ways in which compliance with screening examinations can be improved. 
 
Increasing diabetic patients’ knowledge of DR improves their understanding and acceptance of 
the importance of routine eye examinations for early detection and treatment. Studies conducted 
in Hyderabad and Tamil Nadu found that better knowledge of diabetic retinopathy leads to lower 
prevalence of visual impairment and blindness from diabetic retinopathy, and decreases the cost 
associated with eye care in diabetics.(2,14) The literature yielded little information about the 
effectiveness of different methods of educating diabetic patients about retinopathy. 
 
5. Shortfalls in the literature 
• Few studies assessed diabetics’ understanding of the risk factors that play a role in the 
development of DR. 
• Little is known about diabetics’ understanding of the importance of annual retinal 
examinations to detect STDR. 
• Little is known about diabetics’ understanding of the treatment of DR. 
• Few studies assessed a possible difference in awareness of DR between the different 
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To investigate the awareness of diabetic retinopathy (DR) amongst diabetics in the Cape Town 
Metropole. 
Methods 
A population-based cross-sectional survey was conducted as part of the Rapid Assessment of 
Avoidable Blindness (RAAB) survey that was done in 2010 in Cape Town. 
Results 
Of the 1784 eligible survey participants, 305 were known to be diabetic and 226 (80%) of those 
were aware of DR.  Diabetics’ understanding of measures to prevent DR was as follows: 
following a diabetic diet 43 (46%), using diabetic medication 126 (40%), maintaining good 
glycaemic control 54 (17%) and maintaining good blood pressure control 6 (2%).  Ninety (29%) 
diabetic participants were not aware of preventative measures. Type 1 (insulin dependent) 
diabetics were significantly more aware of DR than type 2 (non-insulin dependent) diabetics 
(97% versus 75% respectively: p=< 0.0001). There was no significant difference in awareness 
between diabetics receiving treatment in the private sector versus those receiving treatment in the 
public sector. Of the known diabetics, 136 (48%) were aware that annual retinal examinations 
are recommended and 198 (70%) were not aware what the treatment is for DR. 
Conclusion 
Although many diabetics are aware that diabetes can adversely affect their eyes, they have a poor 
understanding of the risk factors for the development of DR, the importance of retinal 
examinations and the treatment available for DR. 
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Introduction 
According to the World Health Organization (WHO), over the next two decades there will be a 
significant increase in the number of people with type 2 diabetes mellitus (DM). In developing 
countries, the projected increase is estimated to be 150%, from 30 million in 2000 to 80 million 
in 2030.(1) Population-based surveys performed in urban Sub-Saharan Africa have estimated the 
prevalence of diabetes to be between 1.5% among people aged 24–74 years old in Cameroon, 
and 8.2% among people aged 25 years and older in South Africa.(2)  
 
Diabetic retinopathy (DR) is a potentially blinding complication of diabetes, and is the leading 
cause of blindness in working-age populations in high-income settings.(3) DR is expected to 
become an increasingly dominant cause of vision loss in low- and middle-income countries 
(LMICs) such as South Africa, as the diabetes epidemic unfolds and other blinding conditions 
such as cataracts are better controlled.  
 
The risk factors for developing DR are the increased duration of diabetes, poor glycaemic control, 
pregnancy, hypertension, nephropathy, hyperlipidaemia, smoking, obesity and anaemia. The 
impact of untreated DR is significant, not only in terms of the loss of quality of life, but also in 
terms of the cost of health care.(4) Greater awareness of DR, the risk factors for developing DR 
and the need for retinal screening is critical for the timely diagnosis and early treatment of the 
disease.(5) In South Africa, DR is the third leading cause of blindness after cataracts and 
glaucoma, and is responsible for 5% of cases of blindness.(6) 
 
The subjective experience of doctors working in the ophthalmology department at Groote Schuur 
Hospital is that diabetics have a poor awareness of DR, the risk factors for DR and the treatment 
of DR, and that the majority of diabetics presenting with advanced eye disease do not undergo 




Two objectives of the study were to assess the level of awareness of DR amongst diabetics in the 
Cape Town Metropole and their understanding of possible preventative measures to delay the 
onset of DR. Other objectives were to investigate whether awareness of DR varies according to 
subtype of diabetes, education level and socio-economic status, as well as the source of treatment 
(public or private sector). 
Materials and methods 
A RAAB survey was undertaken in Cape Town between September 2010 and November 
2010.(7) A diabetes mellitus (DM) and diabetic retinopathy (DR) component was included in 
selected clusters. 
 
Study sample  
For the RAAB survey, a sample size of 3077 was selected based on a 3% prevalence of blindness 
amongst people aged 50 years and older, a 25% precision rate, a design effect of 1.4, a 95% 
confidence rate and a 10% non-response rate. In total 77 clusters of 40 people were required. For 
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logistical reasons 82 clusters were included. For the DR component, a sample of 2061 was 
required (52 clusters of 40 people), based on an expected DR prevalence of 4.5% (8) and the 
parameters mentioned above.  
 
The 2001 census data were used as the sampling frame and updated using expected population 
growth. Clusters (‘small areas’) were selected by probability proportionate to size. Two-thirds of 
the clusters were randomly allocated to the RAAB+DR survey, while the remaining clusters 
were allocated to the standard RAAB survey only. Two clusters were considered unsafe and 
were replaced by selecting the next suitable area on the sampling frame list. 
 
After the first week of the survey, it was apparent that information gathering from clusters of 40 
people using the RAAB+DR protocol was not manageable for one team in a single day. 
Therefore the RAAB+DR cluster size was reduced to 35 people, and two clusters were randomly 
selected from the ‘RAAB only’ group and allocated the RAAB+DR protocol in order to maintain 
an adequate sample size for the DR component. 
 
Rapid assessment of avoidable blindness 
Detailed descriptions of the RAAB methods are presented in other literature.(8) In summary, 
households within clusters were selected using ‘compact segment sampling’, whereby one 
segment containing approximately 40 (or 35) people aged 50 years or over was randomly 
selected for each cluster.(9) The survey team paid door-to-door visits to households in selected 
segments to identify eligible people until the target cluster size was reached.  Visual acuity (VA) 
was measured using a tumbling ‘‘E’’ chart.  People with eyes with a VA of less than 6/18 were 
examined by the ophthalmologist to assess the primary cause of vision loss. 
 
Diabetes mellitus and diabetic retinopathy components 
In the RAAB+DR clusters, participants were asked whether they had ever been diagnosed with 
diabetes by a health professional and whether they were taking diabetic medication. Random 
blood glucose (RBG) was tested in all participants using a digital glucometer. Participants were 
classified as diabetic if they had had a previous diagnosis of diabetes, were receiving treatment 
for glucose control, or had a RBG ≥11.1 mmol/l.(10)  
 
Additional variables 
Data were collected on age, gender, education and asset ownership, from which a socio-
economic status (SES) index was created using principal component analysis.(11) Previously 
diagnosed diabetics were asked about their history of diabetes and eye examinations.  
  
Survey teams and training 
A questionnaire was compiled in English and Afrikaans. The two versions of the questionnaire 
were piloted on two consecutive days to assess whether patients understood the questions and 
whether the answers could be matched to the options on the questionnaire. There were five 
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survey teams, each consisting of one ophthalmologist and two community-based eye workers. 
The survey teams received six days of training.    
 
Ethical considerations 
Ethical approval for RAAB+DR was granted by the University of Cape Town Health Sciences 
Human Ethics Committee and the London School of Hygiene & Tropical Medicine. All 
participants with ophthalmic conditions that required treatment or further investigation were 
referred accordingly. People with newly diagnosed or poorly controlled diabetes were referred to 
the nearest health centre. The purpose of the study and the examination procedure was explained 
to the subjects, and informed written consent (or in some cases thumb-printed consent) was 
obtained prior to completion of the questionnaire.  
 
The questionnaire 
A questionnaire was completed by all known and newly diagnosed diabetics in the sample. 
 
Data analysis 
The same data were entered into two databases by two different people. Inconsistencies in data 
entry were identified using Epi InfoTM (epidemiology statistical software), and corrections were 
made by referring back to the original data capture sheets. The data was then analysed using 
STATA 11 (data analysis and statistical software).  
 
Results 
The total number of eligible survey participants in the RAAB and DR clusters was 2110, of 
which 1872 were examined in the survey. 119 (16%) people were unavailable, 116 (5%) 
declined to participate and 3 (0.1%) were unable to communicate with the survey teams. Out of 
the 1872 people included in the RAAB+DR survey, diabetes status was assessed in 1784 
participants (95%), of whom 343 were found to have diabetes (19.1% 95% CI 16.7–21.6). Out of 
343 people with diabetes, 305 (89%) were already known diabetics. The questionnaire was 
completed by 284 of the 343 diabetic participants, which equates to a response rate of 93%.  
 
What proportion of diabetics is aware of diabetic retinopathy? 
Table 1 indicates that 80% of known diabetics in the Cape Town Metropole are aware of DR as a 
possible complication of diabetes. When comparing the awareness of DR between private and 
public sector patients, the results showed that 63 diabetics (86%) in the private sector were aware 
of DR, and 153 diabetics (80%) in the public sector were aware of DR, as shown in Table 2 (p-
value 0.27). Table 2 also reveals that 69 type 1 diabetics (97%) were aware of DR as a possible 
complication compared to 155 of type 2 diabetics (75%).  
 
PAGE 34 
Table 1: Knowledge and awareness of eye complications of diabetes among people with 










Can diabetes affect the eyes?     
No 72 (23%) 17 (57%) 55 (20%) <0.0001 
Yes (correct answer) 239 (77%) 13 (43%) 226 (80%)  
     
Can glasses can help?     
No (correct answer) 91 (29%) 8 (27%) 83 (30%) 0.05 
Yes 113 (36%) 6 (20%) 107 (38%)  
Don’t know 107 (34%) 16 (53%) 91 (32%)  
     
How often should eyes be 
examined? 
    
At least once a year (correct 
answer) 
145 (46%) 9 (30%) 136 (48%) 0.04 
Less than once a year 16 (5%) 0 (0%) 16 (6%)  
Don’t know 152 (49%) 21 (71%) 131 (46%)  
*P-value comparing new/known diabetics using chi square or Fisher’s exact test. 




Table 2: Comparison of responses between type 1 and type 2 diabetics, and between public 
and private sector patients (known diabetics only) 
 Type of diabetes Source of diabetes medicine 
 Type 1 Type 2 p-value Public Private p-value 
Can diabetes affect the 
eyes? 
      
Yes 53 (25%) 2 (3%) <0.001 37 (19%) 10 (14%) 0.27 
No 155 (75%) 69 (97%)  153 (80%) 63 (86%)  
       
Can glasses help?       
No 62 (29%) 21 (30%) 0.95 46 (24%) 34 (47%) 0.002 
Yes 81 (38%) 25 (36%)  76 (40%) 22 (30%)  
Don’t know 68 (32%) 23 (33%)  69 (36%) 17 (23%)  
       
How often should eyes 
be examined? 
      
At least once a year 98 (47%) 38 (54%) 0.49 95 (49%) 37 (51%) 0.004 
Less than once a year 13 (6%) 3 (4%)  5 (3%) 9 (12%)  
Don’t know 100 (47%) 29 (41%)  92 (48%) 37 (37%)  
*P-value using chi square or Fisher’s exact test. 




Table 3: Association between the awareness of diabetic retinopathy and socio-economic 
variables 
 Can diabetes affect the 
eyes? 
Can glasses help? How often should eyes be 
examined? 
 Yes No p-
value 
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 Can diabetes affect the 
eyes? 
Can glasses help? How often should eyes be 
examined? 
 Yes No p-
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Type of diabetes 






















































*P-value using chi square or Fisher’s exact test. 
SES/education: these figures show trends that increased awareness is associated with higher 
education and SES level, but not all of these correlations are statistically significant. 
Note: Some questionnaire responses were missing. 
 
What is diabetics’ understanding of the risk factors that play a role in the 
development of diabetic retinopathy? 
From Table 4 it is apparent that 90 diabetics (29%) were unaware of measures that may prevent 
DR. In terms of possible preventive actions, 143 diabetics (46%) thought that a diabetic diet was 
important and 126 diabetics (40%) thought that taking diabetic medication was important. 
 
 
Table 4: Breakdown of the actions that diabetics thought could prevent diabetes-related 
eye damage. 
 Number % 
Diabetic diet 143 46% 
Taking medication as 
prescribed 126 40% 
Exercise 60 19% 
Losing weight 23 7% 
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Number % 
Keeping blood sugar under 
control 54 17% 
Keeping blood pressure under 
control 6 2% 
Other 19 6% 
Don’t know 90 29% 
What is diabetics’ understanding of the importance of retinal examinations to 
detect STDR and the treatment of STDR?  
The results shown in Table 1 demonstrate that 136 diabetics (48%) were aware that annual 
retinal examinations are required, and 131 diabetics (46%) did not know how often they should 
go for a retinal examination. 
The treatment for STDR is argon laser photocoagulation and intravitreal anti vascular endothelial 
growth factor injections. In the survey, diabetics were asked whether they believed that glasses 
would help in the treatment of diabetes-related eye damage. Over a third of diabetics believed 
that glasses would help. A third of diabetics was unaware of the existence of treatment for DR. 
Discussion 
To the best of the authors’ knowledge, this  survey is the first  population-based survey in Africa 
on the awareness of DR in diabetics, the risk factors for DR and the need for retinal screening for 
DR, and one of only a few conducted internationally.(1,5,12) 
The results of this study indicate that the majority of diabetics in the Cape Town Metropole are 
aware that diabetes can affect their eyes, which is not in keeping with the subjective experience 
of doctors working in the Groote Schuur Hospital’s Eye Clinic, an example possibly of the 
skewed experience of practitioners in a tertiary institution.  The awareness level of DR in Cape 
Town is similar to that found in some studies(13-16), but much better than that found in other 
studies(1,12,17). An interesting finding of this study is that diabetics obtaining treatment in the 
private sector do not have a greater awareness of DR than those being cared for in the public 
sector. This finding belies the assumption that diabetics receiving medical care in the public 
sector would be less informed about their disease due to public sector medical personnel having 
less time to impart relevant information, compared to medical personnel in the private sector.  
This study showed that both a higher socio-economic status and a better education level 
correlated with a better awareness of DR, which was in keeping with several other studies in the 
literature.(1,5,12,16,18,19) One possible reason for this correlation might be that diabetics who 
are better educated are better able to understand the explanations given to them by health care 
personnel about diabetes and its complications, and may have greater access to both written and 
audio-visual health information in the public domain.  
It is clear from this study, that being aware that diabetes can affect one’s eyes does not imply an 
understanding of the risk factors for developing DR, possible preventative measures and the need 
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for regular screening examinations. Interestingly, a relatively high proportion of diabetics 
highlighted the need for following a diabetic diet and taking diabetic medication, but a much 
smaller proportion understood the importance of glycaemic control. A disturbingly high 
proportion of patients (29%) were not aware of any measures they could implement to help 
prevent DR. 
To prevent diabetics from losing their sight due to STDR, diabetics should have annual retinal 
examinations to detect STDR. However diabetics in this study have a very poor understanding of 
the need for retinal examinations. The finding that a relatively low proportion of diabetics are 
aware of the need for regular retinal examinations is in keeping with data from several other 
studies.(12,15,16,18) Despite the clear value of laser photocoagulation in preventing visual loss 
from STDR, diabetics in Cape Town have a poor understanding of the treatment of DR, with a 
sizable proportion of patients (38%) believing that spectacles will help to restore vision.  
In summary 
This study provides the first population-based data in Africa that demonstrate that despite a 
reasonable level of awareness of DR as a possible complication of diabetes (80%), many have a 
poor understanding of the risk factors for the development of DR, a poor understanding of the 
importance of annual retinal examinations and a lack of knowledge about the treatment of DR. 
The study findings suggest that awareness of the importance of the control of systemic risk 
factors in the prevention of DR and the need for regular retinal examinations needs to be greatly 
improved.  This increased awareness, combined with access to and uptake of retinal screening 
and DR treatment services, should result in a decrease in the prevalence of visual impairment and 
blindness due to diabetic eye disease in Cape Town. 
Limitations of the study 
The questionnaire was compiled in Afrikaans and English. Xhosa-speaking community eye 
workers translated the questionnaire into Xhosa during interviews with Xhosa-speaking diabetics. 
This could have introduced bias into the results. Univariate analysis was only performed when 
examining the relationship between variables such as awareness, socio-economic level and 
education level. 
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  Participant information sheet 1.
a. English version
Participant information sheet: Survey of blindness and diabetic eye disease in Cape Town 
What is the purpose of the study? 
We are doing a study to find out how many people in Cape Town are blind and what the causes 
of blindness are. People with diabetes can develop an eye disease which can damage sight. As 
diabetes is a big problem in South Africa, we would also like to find out the best way to diagnose 
eye disease from diabetes during community surveys of blindness. We hope this information will 
help the planning of eye care services in Cape Town  
What will happen if I agree to take part in the study? 
• We will ask you a few questions about yourself.
• You will then have your eyesight checked and your eyes examined by a doctor.
• We will then do a finger prick blood test to see whether or not you might have diabetes. If the
test shows that you might have diabetes, you will be given some eye drops so that the doctor
can examine your eyes in more detail to see if the diabetes has affected your eyes. The eye
drops may sting a little and may make your vision blurred for a few hours, and you should
not drive until your vision has returned to normal.
• If you may have diabetes and show some changes in your eyes on examination, we will give
you an appointment to attend Groote Schuur Hospital on a Saturday morning for a thorough
eye check.
• When you get to the hospital, we will pay you R150.00 to cover the cost of your transport to
and from hospital.
Why have I been chosen? 
We have randomly chosen areas in Cape Town and are inviting all people aged over 50 years in 
these areas to take part. You’ve been chosen because your house is in one of these areas. 
What are the advantages to me to take part in the study? 
You will receive a free vision test. If anything abnormal is detected, you will receive a free eye 
examination with further referral for treatment if needed. You will also be tested for diabetes. 
This is useful, as many people who have diabetes do not know they have the condition and so are 
not on treatment for it. 
Confidentiality 
All information which is collected about you during the study will be kept strictly confidential. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you decide to take part you are still 
free to withdraw at any time and without giving a reason.  
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If you have any other questions that are not answered here, or which need any further 




Deelnemer inligtingsblad: Opname van blindheid en diabetiese oogsiekte in Kaapstad, Suid-
Afrika. 
Wat is die doel van die studie? 
Ons is besig met ’n studie om uit te vind hoeveel mense in Kaapstad blind is en wat die oorsaak 
van die blindheid is. Persone met suiker diabetes kan ’n oogsiekte ontwikkel wat hulle sig kan 
beskadig. Aangesien diabetes ’n groot probleem in Suid- Afrika is, wil ons ook uitvind wat die 
beste manier is om oogsiekte a.g.v. diabetes gedurende gemeenskap opnames te diagnoseer. Ons 
hoop hierdie  inligting sal die beplanning van oogsorg dienste in Kaapstad. 
Wat sal gebeur as ek instem om deel te neem aan die studie? 
• 'n Dokter sal jou gesigsvermoë nagaan en jou oë toets.
• Ons sal dan ’n vinger prik bloedtoets doen om vas te stel of jy diabetes mag hê of nie.
• As die toets toon dat jy wel diabetes mag hê, sal jy oogdruppels gegee word sodat die dokter
jou oë beter kan toets om vas te stel of jou oë skade opgedoen het a.g.v. diabetes. Die
oogdruppels mag ’n bietjie brand en mag ook jou visie vir ’n paar uur verdof. Dit sal
veroorsaak dat jy vir die res van die dag nie sal kan bestuur nie. Ons sal jou verwys vir
behandeling as jy ’n oogprobleem het of moontlik diabetes.
• As die vinger prik bloedtoets toon dat jy diabetes mag hê, sal ons vir jou ’n afspraak maak by
Groote Schuur hospital op ‘n Saterdag, vir ’n deeglike ondersoek van jou oë. Wanneer jy by
die hospitaal opdaag, sal ons jou R150.00 betaal om jou vervoerkoste na die hospitaal en huis
te dek.
Hoekom is ek gekies? 
Ons het d.m.v. ’n steekproef gebiede in Kaapstad gekies en nooi alle persone oor 50 jaar in 
hierdie gebiede om deel te neem aan die studie. Jy is gekies omdat jou huis in een van hierdie 
gebiede val. 
Wat is die voordele indien u aan die studie deelneem? 
U sal ‘n gratis visietoets ontvang en indien u visie nie normaal is nie, ook ‘n gratis oogondersoek 
en verwysing indien nodig. U sal ook getoets word vir diabetes. Die rede is omdat baie mense 
met diabetes nie weet hul het diabetes nie en gebruik daarom nie behandeling nie. 
Vertroulikheid 
Alle inligting wat oor jou versamel is met die studie is streng vertroulik 
Moet ek deelneem? 
Nee. Dit is jou besluit om deel te neem of nie. As jy besluit om deel te neem is jy steeds vry om 
enige tyd te onttrek en u hoef nie ‘n rede te gee nie. 
As jy enige vrae het wat nie hier beantwoord is nie of as jy enige ander inligting of 




Uxwebhu lwenkcukacha lomthathi nxaxheba: Ucwaningo lwesifo zamehlo kunye neswekile 
eKapa, eMzantsi Afrika. 
Ingaba yintoni injongo yoluphando? 
Senza oluphando ukufumanisa ukuba bangaphi abantu apha eKapa abangaboniyo kwaye 
kudalwa yintoni ukungaboni/iyintoni ekudalayo. Senza uphandoukuze sifumanisise ukuba 
bangaphi abantu eKapa abangaboniyo kwaye yintoni ebangela ukungaboni. Abantu abanesifo 
seswekile bangathi babe nesifo samehlo esithi simoshe amehlo.Kuba ke isifo seswekile siyingxaki 
enkulu eMzantsi Afrika,singathanda ukufumana indlela hlola isifo samehlo kwiswekile ngexesha 
kwenziwa uphando lokungaboni ekuhlaleni.  Siyathemba ukuba ezinkcukacha kungathi kukwazi 
ukuncedisa ekuncwangciseni inkonzo zoku khathalela amehlo apha eKapa kunye nezinye 
izixeko kwalapha eMzantsi Afrika. 
Ingaba kuzokwenzeka ntoni ukuba ndithe ndavuma ukuba yinxalenye yoluphando? 
Sizokuthi sikubuze imibuzo embalwa ngawe kunye nabantu abahla endlini yakho.Uyokuthi 
ujongwe amehlo kwaye amaehlo akho axilongwe nguqgirha.Sizokuthi senze utsalo gazi kumnwe 
wakho ukuze sibone  okanye unayo okanye awunaso isifo seswekile. Ukuba iziphumo zithi 
kungase ubenaso isifo seswekile, unikwe iyeza lamehlo ukwenzela uqgirha awaxilonge 
ngokucophelela ukuze abone ukuba yintoni unobangela kumehlo akho kwisifo seswekileto . 
Iyeza lamehlo lingathi likuphandle kancinci kwaye ingenza ukuba ibengathi amehlo abenkungu 
okweyure ezimbalwa.  Kuyofuneka ulinde unde uzive ukuba unofifi lokubona kakuhle 
ngaphambi kokuba uqhube. Singathi sikuthumele kwindawo onokufumana khona amayeza 
amehlo ukuba unegxaki yamehlo okanye yesifo seswekile. Ukuba ingaba unokuba nesifo 
seswekile kwigazi elitsalwe emnweni kwaye kunotshitsho kuxilongo lwamehlo akho,siyakuthi 
sikunike usuku lokuya kwisibhedlele iGroote Schuur Hospital ngentseni yangomqibelo ukuze 
uzojongwa ngokucophelela amehlo akho. Xa ufika esibhedlele uyakuthi ubhatale R150.00 leyo 
iyakuthi ibe yimali yokukusa esibhedlele nokukubuyisela ekhaya kwakhona. 
Kutheni niye nakhetha mna? 
Sithi sikhethe indawo apha eKapa ngokuqikelela kwaye simeme bonke abantu abangaphezulu 
kweminyaka e50 kwezindawo ukuze bathathe inxaxheba koluphando.  Uye wakhethwa kuba 
kaloku indlu yakho ithe yayinxalenye yezithe zakhethwa kulendo. 
Ingaba zintoni endizokuzizuza xa ndithatha inxaxheba koluphando. 
Uyokuthi ufumane ukuhlolwa amehlo felefele kuba akalunganga, Uxilongo lufelefele luyakuthi 
lukufumanise amayeza amehlo xa efuneka. Uyakuthi uhlolwe nesifo seswekile.Lento iyokuthi 
ibe luncedo kuba abantu abaninzi abanesifo seswekile abayazi ukuba banaso lonto ibenze ukuba 
bangathathi mayeza wayo. 
Inkcukacha ziyimfihlo 
Lonke ulwazi oluzothi luqukathwe apha liyokuthi ligcinwe emfihlakalweni kwaye alunokuthi 
lusetyenziswe nakubanina.  
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Ingaba ndinyanzelekile ukuba ndithathe inxaxheba? 
Hayi. Kuxhomekeke kuwe ukuba uyafuna ukuthatha inxaxheba okanye hayi. Ukuba uthi uthathe 
isiqhibo sokuthatha inxaxheba usavumelekile ukuba urhoxe xa ufuna nanini na ngelixesha 
kwenziwa uphando ngaphandle kokunika izizathu.  
Ukuba unemibuzo  ethe ayaxukushwa/yaphendulwa apha  okanye ufuna ulwazi oluthe chatha 
uyacelwa ukuba uqhaqhamshelane noqgirha u: Nicky Cockburn, kwisibhedlela saseGroote 




Survey of blindness and diabetic eye disease in Cape Town, South Africa 
Cluster:  ________  ID: ________ 
Participant: (first and last name) 
___________________________________ 
I understand what will happen if I take part in this study. 
I have been given the opportunity to ask questions and my questions have been answered. 
Taking part in this study is voluntary. 
I agree to take part in this study. 
Signature / thumb print (participant)  
……………………………………………… 







Opname van blindheid en diabiese oogsiekte in Kaapstad, Suid Afrika 
Cluster:  ________                ID: ________ 
Deelnemer: (naam en van) 
___________________________________ 
Ek verstaan wat sal gebuur as ek aan hierdie studie deelneem. 
Ek het die geleentheid gekry om vrae to vra. 
Ek is bewus dat ek vrywillig aan di studie kan deelneem of nie. 
Ek stem in om deel te neem aan hierdie studie. 
Handtekening / duimafdruk (deelnemer) 
……………………………………………… 




Datum:  ……………………………. 
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c. Xhosa version
Uxhwebhu lwenkcukacha lomthathi nxaxheba:Ucwaningo lwesifo zamehlo kunye neswekile 
eKapa,eMzantsi Afrika 
Iqela:   ________ Isazisi: ________ 
Umthathi nxaxheba: ( Amagama onke) 
___________________________________ 
Ndinalo ulwazi ukuba kuzokwenzeka ntoni xa ndithatha inxaxheba koluphando. 
Ndiye ndalinikwa ithuba lokubuza imibuzo kwaye ithe imibuzo yam yaphendulwaI . 
Ukuthatha inxaxheba koluphando lokokuthanda kum kwaye ndingarhoxa nanini na. 
Tyikitya /Faka ubhontsi - (umthathi nxaxheba )   
……………………………………………… 
Bala igama (Ingqina) 
……………………………………………… 






Cluster: Individual no.: 
* For known diabetics, complete all questions (1-16)
* For newly diagnosed diabetics ask questions 10, 14, 15, 16 (shaded in grey) only
1 What age were you when you were told you had diabetes? Age years YEAR:
2 Are you currently receiving treatment for your diabetes? O (0) No (go to Q5) O (1) Yes (go to Q 3)
3 What treatment do you currently receive for your diabetes? O (1) Diet O (9) N/A
(circle all that apply) O (2) Tablets
O (3) Insulin
O (4) Other. Specify:
4 Where do you normally go to get your diabetic medication? O (1) Government clinic or hospital O (9) N/A
O (2) Private doctor or chemist
O (3) Other. Specify:..............................
5 Where do you usually go for your diabetes check ups? O (1) Government clinic or hospital O (9) N/A
O (2) Private doctor or chemist
O (3) I don't have diabetes check ups
O (4) Other. Specify:..............................
6 Do you have a machine for testing your blood sugar at home? O (0) No (go to Q10) O (1) Yes (Go to Q 7)
O (9) N/A
7 If yes, have you used this to test your blood sugar O (0) No (go to Q9) O (1) Yes (go to Q8)
in the past 4 weeks? O (9) N/A
8 If yes, how often do you usually check your blood O (1) Less than once a month O (9) N/A
sugar at home? O (2) ≥ once a month, but <once a week
O (3) At least once a week
O (4) Once a day
O (5) More than once a day
O (6) When I feel unwell
9 If no, why not? O (9) N/A
(Record response given)
10 When did you first know that diabetes can affect your eyes? O (1) Today O (2) Before today
* Was it today or before today?
11 Did a nurse, doctor or optometrist ever advise you to have your O (0) No O (1) Yes
eyes examined because of your diabetes
12 Before today, have you ever had your eyes examined specifically
to check whether diabetes has affected them or not  - O (0) No (go to Q14) O (1) Yes (go to Q 13)
e.g. Drops were put in your eyes before the examination or 
a photograph was taken of the back of your eye?
13 If yes, has this examination been done by a.....
(ask Qa-g) a Nurse O (0) No O (1) Yes O (9) N/A
b Optometrist (person who tests for glasses)O (0) No O (1) Yes
c Doctor at government clinic or hospital O (0) No O (1) Yes
d Private doctor O (0) No O (1) Yes
e Camera O (0) No O (1) Yes
g Other. Specify__________________________O (0) No O (1) Yes
14 If yes, have you had your eyes examined because O (0) No O (1) Yes 
 of your diabetes in last 12 months?
15 How often do you think people with diabetes should have their O (1) More than once a year
* eyes examined because of their diabetes ? O (2) Once a year
O (3) Every 2 years
O (4) Less than every 2 years
O (5) When they have problems with their eyes
O (6) Don't know
16 If diabetes affects your eyes, will glasses make them better? O (0) No O (1) Yes O (2) Don't know
17 What can a person with diabetes do to decrease the chance of O (1) Diabetic diet
* diabetes affecting their eyes? O (2) Taking diabetic medication as prescribed
O (3) Exercise
O (4) Loose weight
O (5) Keep blood sugar under control
O (6) Keep blood pressure under control, if high
O (7) Other. Specify:_____________________
O (8) Don't know
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b. Afrikaans version
Klein Area: Individuele no.: 
* Vir bekende diabete, voltooi alle vrae(1-16)
* Vir nuutgediagnoseerde diabete vra allenlik vrae 10, 14 ,15, 16(in grys) 
1 Op watter ouderdom is u in kennis gestel dat u diabetes het? Ouderdom jare JAAR:
2 Gebruik u huidiglik behandeling vir u diabetes? O (0) Nee(na Vr5) O (1) Ja(Na Vr3)
3 Watter behandeling gebruik u huidiglik vir u diabetes? O (1) Dieet O (9) NVT
(omsirkel almal van toepassing) O (2) Tablette
O (3) Insulien
O (4) Ander. Spesifiseer: ..............................
4 Waar kry u gewoonlik u diabetiese medikasie? O (1) Staatskliniek of -hospitaal O (9) NVT
O (2) Privaatdokter of apteek
O (3) Ander.Spesifiseer:..................................
5 Waar gaan u gewoonlik vir u diabetes opvolg besoeke? O (1) Staatskliniek of -hospitaal O (9) NVT
O (2) Privaatdokter of apteek
O (3) Ek het nie diabetes opvolg besoeke
O (4) Ander.Spesifiseer:................................
6 Het u 'n masjien om u bloedsuiker by die huis te toets? O (0) Nee (na Vr10) O (1) Ja(Na Vr7)
O (9) NVT
7 Indien ja, het u dit die afgelope 4weke gebruik om u bloedsuiker O (0) Nee(Na Vr9) O (1) Ja(Na Vr8)
te toets? O (9) NVT
8 Indien ja, hoe gereeld toets u  u bloedsuiker O (1) Minder as een keer per maand? O (9) NVT
by die huis? O (2) ≥ een/ per maand,maar < een keer/ week
O (3) Ten minste een ker per week
O (4) Een keer per dag
O (5) Meer as een keer per dag
O (6) Wanneer ek sleg voel
9 Indien nee, hoekom nie? O (9) NVT
(Noteer die antwoord)
10 Wanneer het u uitgevind dat diabetes u oë kan beïnvloed? O (1) Vandag O (2) Voor vandag
Was dit vandag of voor vandag?
11 Het 'n suster,dokter of optometris u ooit in kennis gestel om u oë O (0) Nee O (1) Ja
te laat ondersoek omdat u diabetes het?
12 Het u ooit voor vandag u oë laat ondersoek spesifiek om te toets 
of diabetes u oë beïnvloed het of nie- O (0) Nee(na Vr 14) O (1) Ja(Na Vr13)
bv. Was druppels voor die ondersoek in u oë geplaas of 
  'n foto geneem van die agterkant van die oog?
13 Indien ja, was die ondersoek gedoen deur.....
(Vrae Vr.a-g) a Suster O (0) Nee O (1) Ja O (9) NVT
b Optometris (persoon wat vir brille toets) O (0) Nee O (1) Ja
c Dokter  by staatshospitaal of -kliniek O (0) Nee O (1) Ja
d Privaatdokter O (0) Nee O (1) Ja
e Kamera O (0) Nee O (1) Ja
g Ander.Spesifiseer:__________________________O (0) Nee O (1) Ja
14 Indien ja,  was die ondersoek die afgelope 12 maande ? O (0) Nee O (1) Ja
15 Hoe gereeld dink u behoort 'n persoon met diabetes hul oë O (1) Meer as een keer per jaar
laat ondersoek as gevolg van hul diabetes? O (2) Een keer per jaar
O (3) Elke 2 jaar
O (4) Minder as elke 2 jaar
O (5) Wanner daar fout is met hul oë
O (6) Weet nie
16 Indien diabetes u oë beïnvloed sal 'n bril dit beter maak? O (0) Nee O (1) Ja O (2) Weet nie
17 Wat kan 'n persoon met diabetes doen om die kans te verminder O (1) Diabetiese dieet
dat diabetes hul oë beïnvloed? O (2) Neem diabetes medikasie soos voorgeskryf
O (3) Oefening
O (4) Gewigsverlies
O (5) Hou bloedsuiker onder beheer
O (6) Hou bloeddruk onder beheer as dit hoog is
O (7) Ander.Spesifiseer:_____________________
O (8) Weet nie
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